During this time of extremely high call volume, our team is working diligently to respond to inquiries as quickly as possible on the day they are received. 

  

If you have not received a response from our team or your submitted documents show as pending in your portal, please know these are in queue to be reviewed in the order they are received. Submitting multiple emails, portal messages, or phone calls adds time to the review process for our team and results in additional delays in our ability to respond to inquiries.  

  

To help us better assist you, please utilize one of the following options: 1. Visit your respective patient, provider, or pharmacy portal to enroll, re-enroll, or check grant status. It takes approximately 10 minutes to apply on average, and your application is acted on in real time: https://healthwellfoundation.my.salesforce-sites.com/patients.  2. Email grants@healthwellfoundation.org if your inquiry cannot be answered via the portals. 3. Request a callback through our interactive voice response system and a representative will respond to your inquiry on the same day it is received (note, this may be outside of normal business hours). 

  

We understand the importance of timely and complete responses and serving you is our number one priority. Please help us help you by submitting one inquiry only.  

  

Thank you for your patience during this time. 

Dismiss alert
By Real World Health Care Editorial Staff  |  Sep 21, 2022

American Cancer Society Funds Pioneering Research in Acute Lymphoblastic Leukemia

September is Childhood Cancer Awareness Month, an observance recognized by health care institutions, advocacy organizations, patients and families around the world. While childhood cancer is rare, it is the leading cause of disease-related death past infancy in children and adolescents, according to the National Cancer Institute. Acute Lymphoblastic Leukemia (ALL)…more.

By Claire Saxton, Vice President, Education and Outreach, Cancer Support Community  |  Sep 2, 2020

CAR-T Cell Immunotherapy: What to Expect

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda’s Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct…more.

By Lee Greenberger, PhD, Chief Scientific Officer, The Leukemia & Lymphoma Society  |  Aug 19, 2020

The Evolution of CAR-T Therapy

Over the past two decades there’s been tremendous progress in understanding how to harness the body’s immune system to fight cancer. Today, immunotherapy is a mainstay of cancer treatment. One of the most exciting areas of immunotherapy is CAR (chimeric antigen receptor) T-cell therapy. This treatment involves purifying a special…more.

By Real World Health Care Editorial Staff  |  Aug 5, 2020

Multiple Myeloma Research Foundation: CAR-T Cell Therapy Initiatives

Last year, the Multiple Myeloma Research Foundation (MMRF) launched a new, three-year strategic plan to help transform how multiple myeloma is treated and ultimately cured. One of the plan’s three strategic pillars focuses on immunotherapy, including chimeric antigen receptor T-cell (CAR-T) therapy. Real World Health Care spoke with the MMRF’s…more.

By Real World Health Care Editorial Staff  |  Jul 22, 2020

CAR T-Cell Therapy Gave Me Back My Life

Editor’s Note: This week, Real World Health Care shares an inspirational story of a woman who was diagnosed with lymphoma and received treatment with CAR T-cell therapy. “CAR-T Cell Therapy Gave Me My Life Back” is reprinted with permission from the Association of Community Cancer Centers. Updated in April 2020,…more.

By Real World Health Care Editorial Staff  |  Jun 24, 2020

Does CAR-T Cell Therapy Belong in Community Clinics?

CAR T-cell therapy (CAR-T) has emerged as a highly innovative and promising option for patients with cancer. Until recently, the use of CAR-T has been restricted to small clinical trials, primarily with patients with advanced blood cancers. These trials often are conducted at large, academic medical centers in major metropolitan…more.

By Emily Burke, Ph.D., Director of Instruction, BiotechPrimer.com  |  Mar 11, 2020

Search & Destroy: Chimeric Antigen Receptor T-Cells (CAR-T)

Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.

By Krista Zodet, President/CEO, HealthWell Foundation  |  Jan 15, 2020

Welcoming 2020 with New Insights for Patients with Chronic Diseases

Topics in Focus: ALS, CAR T Therapies, Macular Degeneration and Movement Disorders The HealthWell Foundation is proud to be a founding sponsor of Real World Health Care. Since 2013, Real World Health Care (RWHC) has brought you compelling content on health care issues facing Americans. From features on the people,…more.

By Shaji Kumar, MD, Professor of Medicine, Hematology, Mayo Clinic  |  Nov 1, 2017

Multiple Myeloma: Promising New Therapies, But Challenges Remain

This week, our series on multiple myeloma continues as we talk about immunotherapies and other promising new treatments with Shaji Kumar, MD. Dr. Kumar is a professor of medicine in the division of hematology at Mayo Clinic, where he chairs the myeloma group across all three Mayo sites. Dr. Kumar…more.

Categories: General, Multiple Myeloma
Close menu